Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.46 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16870002 | 1.00 | MDM2 (0.52) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL16870156 | 1.00 | MDM2 (0.52) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL18421240 | 1.00 | MDM2 (0.52) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL30193389 | 1.00 | MDM2 (0.52) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL29431191 | 0.97 | MDM2 (0.51) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL23922657 | 0.95 | MDM2 (0.48) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL30193352 | 0.95 | MDM2 (0.48) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL16870092 | 0.95 | MDM2 (0.48) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL30193482 | 0.95 | MDM2 (0.48) | MDM2KMT2APAX8TDP1TLR2 | |
| SCHEMBL1755616 | 0.95 | PAX8 (0.55) | MDM2KMT2APAX8TDP1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS BC INC. (CA) | 2023-08-24 | — | — | US | disclosed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265173-A1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | MPST, TPST2, SULT1A1 | MDM2 2307/4885KMT2A 130/4885PAX8 3409/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | MDM2 2307/4885KMT2A 130/4885PAX8 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.